MedPath

The Effect Evaluation of Laser Acupuncture in Obesity

Not Applicable
Conditions
Obesity
Registration Number
NCT01975168
Lead Sponsor
Kaohsiung Medical University Chung-Ho Memorial Hospital
Brief Summary

A randomized double-blind placebo-controlled crossover trial is conducted. 200 subjects aged above 20 years with body mass index (BMI) more than 25 kg/m2 are randomly divided into 2 groups (Group 1 and Group 2). Group 1 receives laser acupuncture therapy first while Group 2 receives sham laser acupuncture therapy first. After 12 weeks of treatment and 14 days of washout, Group 1 switch to sham laser acupuncture therapy while Group 2 switch to laser acupuncture for 12 weeks. The subjects are treated with a gallium aluminum arsenide Handylaser Trion, which is used to apply at each of the acupuncture points for 10 seconds every time, 3 times per week. The measurements of outcomes are performed in the beginning, weekly during treatment, and monthly after treatment for 3 months.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Body Mass Index over 25 kg/m2 or Waist girth over 80cm in female, waist girth over 90cm in male
Exclusion Criteria
  • Pathmakers user
  • Epilepsy history
  • Pregnancy
  • Immuno-inhibiting agents user
  • Malignancy
  • Skin contacted disease
  • Weight controlled agents user during trial period
  • Eating disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Primary Outcome Measures
NameTimeMethod
body composition12 weeks

body weight

Secondary Outcome Measures
NameTimeMethod
body mass index12 weeks

Trial Locations

Locations (1)

Chinese Medicine Department Clinic, Kaohsiung Medical University

🇨🇳

Kaohsiung, Taiwan

Chinese Medicine Department Clinic, Kaohsiung Medical University
🇨🇳Kaohsiung, Taiwan
Cheng-Che Lin
Contact
+8863121101
abcmacoto@gmail.com
Chen-Cheng Yang
Contact
+886929919132
cheng10042001@yahoo.com.tw
Chen-Cheng Yang, MD
Principal Investigator

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.